The Australasian Diabetes Data Network (ADDN): National benchmarking across the age spectrum

Abstract

Introduction: The ADDN Registry is a national longitudinal prospective database that offers a unique opportunity for the long-term surveillance of diabetes outcomes in both youth and adults with T1D across Australia and New Zealand. The ADDN benchmark report provides a contemporary real-world snapshot of treatment patterns and outcomes on more than 12,000 people with T1D. Methods: Inclusion criteria were diagnosis of T1D with a follow-up visit from 01/01/2017 to 31/12/2017. Outcome measures were HbA1c, Body Mass Index and/or Standard Deviation Scores (BMI-SDS) and insulin regimen: twice daily injection (BD), multiple daily injection (MDI), continuous subcutaneous insulin infusion (CSII) or other. Results: 4791 (49% female) pediatric patients and 1760 (48% female) adult patients from 13 tertiary diabetes centers in NSW, QLD, SA, VIC, WA and New Zealand met the inclusion criteria. In youth (aged < 18.0 years) mean (± SD) age was 12.1 ± 3.9 and T1D duration 4.8 ± 3.8 years. Mean BMI SDS was 0.6 ± 0.9 and HbA1c 8.3 ± 1.4%, with 28% achieving a HbA1c of <7.5% (58 mmol/mol). Overall, 39% were treated with CSII, 38% MDI and 17% with BD regimens. In adults (aged ≥18.0 years at visit) mean age was 39 ± 16, and T1D duration 17.6 ± 13.1 years. Mean BMI was 26.8 ± 5.5 and HbA1c 8.4 ± 1.7%, with 14% achieving a HbA1c of < 7.0% (53 mmol/mol). Overall, 20% were treated with CSII, 57% MDI and 5% with BD regimens. Conclusions: The majority of people with T1D in ADDN do not currently meet the recommendations for glycaemic control or healthy weight. By providing diabetes centers an opportunity to compare their own care practices and outcomes through benchmarking with other centers, ADDN has a pivotal role in driving change in clinical practice and improving patient outcomes.L6266833992019-03-14 <br />